Skip to main content
Top
Published in: Acta Diabetologica 11/2019

01-11-2019 | Insulins | Case Report

Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment

Authors: C. Cosentino, M. Contento, M. Paganini, E. Mannucci, B. Cresci

Published in: Acta Diabetologica | Issue 11/2019

Login to get access

Excerpt

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome are a maternally inherited mitochondrial genetic disorder characterized by defective oxidative phosphorylation. The adenine-to-guanine transition at position 3243 in the MT-TL1 gene is the most common mutation of mitochondrial DNA found in patients with MELAS syndrome. As other mitochondrial disorders, MELAS syndrome can develop in the neonatal phase, childhood, or adulthood, and show a broad spectrum of clinical presentations. Neurological and muscular disturbances (i.e., stroke-like episodes, recurrent migrainous headaches, seizures, and muscle weakness with exercise intolerance) are the earliest and most frequent manifestations of the disease. However, mitochondrial diseases, including MELAS syndrome, are multi-organ disorders including cardiomyopathy, nephropathy, hypothyroidism, and diabetes (DM). …
Literature
1.
go back to reference Yatsuga S et al (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624CrossRef Yatsuga S et al (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624CrossRef
2.
go back to reference Divakaruni SA et al (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14):5422–7CrossRef Divakaruni SA et al (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14):5422–7CrossRef
3.
go back to reference El-Hattab AW et al (2014) Glucose metabolism derangements in adults with the MELAS m.3243A > G mutation. Mitochondrion 18:63–69CrossRef El-Hattab AW et al (2014) Glucose metabolism derangements in adults with the MELAS m.3243A > G mutation. Mitochondrion 18:63–69CrossRef
4.
go back to reference Maedler K et al (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506CrossRef Maedler K et al (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506CrossRef
5.
go back to reference Artuso R et al (2015 Feb) Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J 15(1):49–54CrossRef Artuso R et al (2015 Feb) Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J 15(1):49–54CrossRef
Metadata
Title
Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment
Authors
C. Cosentino
M. Contento
M. Paganini
E. Mannucci
B. Cresci
Publication date
01-11-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 11/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01302-z

Other articles of this Issue 11/2019

Acta Diabetologica 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.